ReviewCancers2022
The Long and Winding Road: An Overview of the Immunological Landscape of Intracranial Meningiomas.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- Tumor-associated macrophages in meningiomas: a novel biomarker for poor survival outperforming the benefits of T cells.Acta neuropathologica · 2025Article
- The importance of the optic nerves unlocking during the resection of anterior skull base meningiomas for visual function preservation: surgical nuances and clinical outcome.Neurosurgical review · 2025Article
- The Molecular and Immunological Landscape of Meningiomas.International journal of molecular sciences · 2024Review
- Single-cell transcriptome analysis upon ECM-remodeling meningioma cells.Neurosurgical review · 2024Article
- Role of Mediterranean diet in the development and recurrence of meningiomas: a narrative review.Neurosurgical review · 2023Review
- The role of radiation therapy and systemic treatments in meningioma: The present and the future.Cancer medicine · 2023Review
- Article
- Liquid biopsy evaluation of circulating tumor DNA, miRNAs, and cytokines in meningioma patients.Frontiers in neurology · 2023Article
- Nanoparticle-Based Drug Delivery Systems Targeting Tumor Microenvironment for Cancer Immunotherapy Resistance: Current Advances and Applications.Pharmaceutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of immunotherapy is gaining ever-increasing interest in the neuro-oncological field, and this is also expanding to the management of intracranial meningioma. Meningiomas are still the most common primary adult tumor of the CNS, and even though surgery and/or radiotherapy still represent cornerstones of their treatment, recent findings strongly support the potential role of specific immune infiltrate cells, their features and genomics, for the application of personalized treatments and prognostic implications. According to the PRISMA guidelines, systematic research in the most updated platform was performed in order to provide a descriptive and complete overview about the characteristics, role and potential implications of immunology in meningioma tumors. Seventy articles were included and analyzed in the present paper. The meningioma microenvironment reveals complex immune tumor-immune cells interactions that may definitely influence tumor progression, as well as offering unexpected opportunities for treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.